Drug testing facilities should be screening for Kratom an opioid with potential for addiction and abuse. It is crucial to understand the physiological and psychological effects of Kratom, and how it is being used as an alternative to other opioids.
In this webinar, Pat Pizzo, a renowned forensic toxicologist, discusses Kratom’s legal status, and the Drug Enforcement Agency (DEA), Food and Drug Administration (FDA), and advocacy groups’ position on its safety and uses. She’ll explore the history of Kratom, where its use is trending in the US, and present data from federal organizations and research communities. Pat will conclude with compelling evidence for incorporating Kratom as part of your drug testing program.
Kratom abuse, as documented by the National Poison Data System (NPDS), is on the rise and there are lingering questions as to its true benefits and potential dangers. Understand what the Drug Enforcement Agency (DEA) and the Food and Drug Administration (FDA) know about Kratom and how that differs from advocacy groups’ perceived benefits. Learn how testing for Kratom can support better outcomes in your treatment programs.
Detailed Learning Objectives:
Complete the form below to access the webinar recording.
DPB Consultants, Inc.
Webinar recorded June 13, 2019.
CE credit not available for this webinar.